Yu Qin

2 clinical trials · Sponsor

Record	Firm	Date
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older (NCT05679466)	Yu Qin	2022-12-27
Sequential Enhanced Safety Study of a Novel Coronavirus Messenger RNA (mRNA) Vaccine in Adults Aged 18 Years and Older. (NCT05568693)	Yu Qin	2022-09-21

Every clearance here is in the API, with alerts when new ones post.